Skip to main content

Advertisement

Log in

Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer

Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Lung carcinosarcoma (PCS) and other histological subtypes of non-small cell lung cancer, such as primary pulmonary lymphoma (PPL), pulmonary carcinoid (PC), and primary pulmonary lymphoepithelioma-like carcinoma (LELC), are rare. For their low incidence, the diagnosis and treatment are still controversial. Some patients only need surgery, while others may need chemotherapy, radiotherapy, or targeted therapy. In this paper, we retrospectively reviewed the literature of some rare histological subtype of NSCLC for the recent 20 years, and try to get some conclusions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Ro JY, Chen JL, Lee JS, Sahin AA, Ordonez NG, Ayala AG. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer. 1992;69(2):376–86.

    Article  CAS  PubMed  Google Scholar 

  2. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18(2):103–20.

    Article  PubMed  Google Scholar 

  3. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 1994;73(12):2936–45.

    Article  CAS  PubMed  Google Scholar 

  4. Chang YL, Lee YC, Shih JY, Wu CT. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer. 2001;34(1):91–7.

    Article  CAS  PubMed  Google Scholar 

  5. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005;40(2):90–7.

    Article  PubMed  Google Scholar 

  6. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 53–8.

    Google Scholar 

  7. Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84(3):973–80.

    Article  PubMed  Google Scholar 

  8. Venissac N, Pop D, Lassalle S, Berthier F, Hofman P, Mouroux J. Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease. J Thorac Cardiovasc Surg. 2007;134(3):619–23.

    Article  PubMed  Google Scholar 

  9. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27(9):1203–15.

    Article  PubMed  Google Scholar 

  10. •• Lin Y, Yang H, Cai Q, et al. Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. Am J Clin Oncol. 2016;39(3):215–22. Retrospective study showed that patients receiving complete resection had better prognosis and neither neoadjuvant nor adjuvant chemotherapy improved patient survival for those with early-stage disease

    Article  CAS  PubMed  Google Scholar 

  11. Arriagada R, Bergman B, Dunant A, Le CT, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.

    Article  PubMed  Google Scholar 

  12. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–97.

    Article  CAS  PubMed  Google Scholar 

  13. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.

    Article  CAS  PubMed  Google Scholar 

  14. Raveglia F, Mezzetti M, Panigalli T, et al. Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg. 2004;78(5):1742–7.

    Article  PubMed  Google Scholar 

  15. Ito K, Oizumi S, Fukumoto S, et al. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer. 2010;68(2):204–10.

    Article  PubMed  Google Scholar 

  16. Langer F, Wintzer HO, Werner M, Weber C, Brummendorf TH, Bokemeyer C. A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicin. Anticancer Res. 2006;26(5B):3893–7.

    PubMed  Google Scholar 

  17. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13(5):466–75.

    Article  CAS  PubMed  Google Scholar 

  18. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35(8):1226–34.

    Article  PubMed  Google Scholar 

  19. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

    Article  CAS  PubMed  Google Scholar 

  20. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005;65(17):7525–9.

    Article  CAS  PubMed  Google Scholar 

  21. Jiang X, Liu Y, Chen C, et al. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases. Clin Lung Cancer. 2012;13(4):288–96.

    Article  CAS  PubMed  Google Scholar 

  22. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125(10):2479–82.

    Article  CAS  PubMed  Google Scholar 

  23. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012;77(3):507–14.

    Article  PubMed  Google Scholar 

  26. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999;17(2):668–75.

    Article  CAS  PubMed  Google Scholar 

  27. Lococo F, Gandolfi G, Rossi G, et al. Deep sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma. J Thorac Oncol. 2016;11(8):1282–92.

    Article  PubMed  Google Scholar 

  28. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802.

    Article  CAS  PubMed  Google Scholar 

  29. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8(6):803–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  PubMed  Google Scholar 

  31. Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J. 2002;20(3):750–62.

    Article  CAS  PubMed  Google Scholar 

  32. Wróbel T, Dzietczenia J, Prochorec-Sobieszek M, Mazur G, Piwkowski P. Primary pulmonary diffuse large B-cell lymphoma. Am J Hematol. 2012;87(1):107–8.

    Article  PubMed  Google Scholar 

  33. Li G, Hansmann ML, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16(6):519–31.

    Article  CAS  PubMed  Google Scholar 

  34. Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–8.

    Article  CAS  PubMed  Google Scholar 

  35. Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–16.

    Article  CAS  PubMed  Google Scholar 

  36. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW. Primary pulmonary lymphoma. Ann Thorac Surg. 2005;80(4):1248–53.

    Article  PubMed  Google Scholar 

  37. Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69(4):993–7.

    Article  CAS  PubMed  Google Scholar 

  38. Nahorecki A, Chabowski M, Straszak E, et al. Primary pulmonary MALT lymphoma—case report and literature overview. Eur Rev Med Pharmacol Sci. 2016;20(10):2065–9.

    CAS  PubMed  Google Scholar 

  39. Feugier P, Von Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma—a study by the Groupe d'Etude des Lymphoma de l'Adulte. J Clin Oncol. 2005;23:4117–26.

    Article  CAS  PubMed  Google Scholar 

  40. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013;31:565–72.

    Article  CAS  PubMed  Google Scholar 

  41. Gisselbrecht C. Can we improve ABVD in Hodgkin’s lymphoma? Lancet Oncol. 2013;14(13):1254–6.

    Article  PubMed  Google Scholar 

  42. Morandi U, Casali C, Rossi G, et al. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg. 2006;18:191–8.

    Article  PubMed  Google Scholar 

  43. Cardillo G, Sera F, Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004;77:1781–5.

    Article  PubMed  Google Scholar 

  44. Kosmidis PA. Treatment of carcinoid of the lung. Curr Opin Oncol. 2004;16:146–9.

    Article  PubMed  Google Scholar 

  45. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg. 2002;123:303–9.

    Article  PubMed  Google Scholar 

  46. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from literature. Chest. 2001;119:1647–51.

    Article  CAS  PubMed  Google Scholar 

  47. Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156–61.

    Article  CAS  PubMed  Google Scholar 

  48. Mezzetti M, Raveglia F, Panigalli T, et al. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg. 2003;76(6):1838–42.

    Article  PubMed  Google Scholar 

  49. Terzi A, Lonardoni A, Feil B, Spilimbergo I, Falezza G, Calabrò F. Bronchoplastic procedures for central carcinoid tumors: clinical experience. Eur J Cardiothorac Surg. 2004;26(6):1196–9.

    Article  PubMed  Google Scholar 

  50. Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007;31(2):186–91.

    Article  PubMed  Google Scholar 

  51. •• Daddi N, Schiavon M, Filosso PL, et al. Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. Eur J Cardiothorac Surg. 2014;45(4):677–86. Retrospective study showed that with the exception of pneumonectomy, the extent of resection of ACs does not seem to affect survival and should be accompanied preferably by lymphadenectomy

    Article  PubMed  Google Scholar 

  52. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010;89(3):998–1005.

    Article  PubMed  Google Scholar 

  53. Kaplan B, Stevens CW, Allen P, Liao Z, Komaki R. Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys. 2003;55(1):125–31.

    Article  PubMed  Google Scholar 

  54. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004;44(2):213–20.

    Article  PubMed  Google Scholar 

  55. Lim E, Goldstraw P, Nicholson AG, et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol. 2008;3(10):1194–201.

    Article  PubMed  Google Scholar 

  56. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA. Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer. 2009;115(19):4434–41.

    Article  PubMed  Google Scholar 

  57. Marquez-Medina D, Popat S. Systemic therapy for pulmonary carcinoids. Lung Cancer. 2015;90(2):139–47.

    Article  PubMed  Google Scholar 

  58. Abdel-Rahman O, Fouad M. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. Future Oncol. 2015;11(8):1275–90.

    Article  CAS  PubMed  Google Scholar 

  59. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.

    Article  CAS  PubMed  Google Scholar 

  60. Yao J, Fazio N, Buzzoni R, et al. ORAL02.02: efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the lung: RADIANT-4 subgroup analysis: topic: medical oncology. J Thorac Oncol. 2016;11((11S):S253.

    Article  Google Scholar 

  61. Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995;103(3):308–15.

    Article  CAS  PubMed  Google Scholar 

  62. Bégin LR, Eskandari J, Joncas J, Panasci L. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J Surg Oncol. 1987;36(4):280–3.

    Article  PubMed  Google Scholar 

  63. Chang YL, Wu CT, Shih JY, Lee YC. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci. 2011;102(1):282–7.

    Article  CAS  PubMed  Google Scholar 

  64. Chen FF, Yan JJ, Lai WW, Jin YT, Su IJ. Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated “lymphoepithelioma-like” carcinoma as a distinct entity with better prognosis. Cancer. 1998;82(12):2334–42.

    Article  CAS  PubMed  Google Scholar 

  65. Higashiyama M, Doi O, Kodama K, et al. Lymphoepithelioma-like carcinoma of the lung: analysis of two cases for Epstein-Barr virus infection. Hum Pathol. 1995;26(11):1278–82.

    Article  CAS  PubMed  Google Scholar 

  66. Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci U S A. 1986;83(23):9006–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Liang Y, Wang L, Zhu Y, et al. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer. 2012;118(19):4748–58.

    Article  CAS  PubMed  Google Scholar 

  68. Dunant A, Pignon JP, Le CT. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res. 2005. 11(13 Pt 2): 5017s–5021s.

  69. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008. 26(21): 3552–9.

  70. Ho JC, Lam WK, Wong MP, et al. Lymphoepithelioma-like carcinoma of the lung: experience with ten cases. Int J Tuberc Lung Dis. 2004. 8(7): 890–5.

  71. Ho JC, Lam DC, Wong MK, Lam B, Ip MS, Lam WK. Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. J Thorac Oncol. 2009. 4(9): 1174–7.

  72. Cohen MH, Justice R, Pazdur R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist. 2009. 14(9): 930–5.

  73. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006. 12(5): 1647–53.

  74. Wang L, Lin Y, Cai Q, et al. Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis. 2015. 7(9): 1556–62.

  75. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009. 115(8): 1723–33.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ying Liang MD, PhD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, H., Lin, Y. & Liang, Y. Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer. Curr. Treat. Options in Oncol. 18, 54 (2017). https://doi.org/10.1007/s11864-017-0494-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0494-9

Keywords

Navigation